PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25415050-7	2015	In vitro experiments using NB cell lines, BE(2)-C, SMS-KCNR, and CHLA90 show that DFMO treatment reduced LIN28B and MYCN protein levels and increased Let-7 miRNA and decreased neurosphere formation.	Eflornithine	82-86	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	116-120	
23440295-0	2013	DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.	Eflornithine	0-4	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	64-68	
23440295-0	2013	DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.	Eflornithine	5-17	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	64-68	
23440295-5	2013	DFMO treatment leads to the accumulation of the cyclin-dependent kinase inhibitor p27(Kip1) protein and causes p27(Kip1)/Rb-coupled G(1) cell cycle arrest in MYCN-amplified NB tumor cells through a process that involves p27(Kip1) phosphorylation at residues Ser10 and Thr198.	Eflornithine	0-4	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	158-162	
23440295-8	2013	DFMO treatments induced MYCN protein downregulation and phosphorylation of Akt/PKB (Ser473) and GSK3-beta (Ser9), and polyamine supplementation alleviated the DFMO-induced effects.	Eflornithine	0-4	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	24-28	
19147568-5	2009	Here, we report that DFMO treatment, but not Odc heterozygosity, impairs MYCN-induced neuroblastoma and that, in this malignancy, transient DFMO treatment is sufficient to confer protection.	Eflornithine	21-25	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	73-77	
19147568-6	2009	The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins.	Eflornithine	36-40	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	60-64	
19147568-6	2009	The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins.	Eflornithine	187-191	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	60-64	
19147568-7	2009	These findings suggest that agents, such as DFMO, that target the polyamine pathway may show efficacy in high-risk, MYCN-amplified neuroblastoma.	Eflornithine	44-48	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	116-120	
34129075-8	2021	Excised tumors revealed that DFMO/probenecid treatment decreases polyamines putrescine and spermidine, reduces MYCN protein levels and dephosphorylates retinoblastoma (Rb) protein (p-RbSer795), suggesting DFMO/probenecid-induced cell cycle arrest.	Eflornithine	29-33	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	111-115	
34129075-8	2021	Excised tumors revealed that DFMO/probenecid treatment decreases polyamines putrescine and spermidine, reduces MYCN protein levels and dephosphorylates retinoblastoma (Rb) protein (p-RbSer795), suggesting DFMO/probenecid-induced cell cycle arrest.	Eflornithine	205-209	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	111-115